University of Montana
Missoula, Montana, 59812, United States
NCT Number: NCT05770401
The goal of this randomized, placebo-controlled, clinical trial is to develop and test the efficacy of an Internet-based behavioral intervention for refractory chronic cough. The main questions it aims to answer are:
* What are the best recruitment pathways to find people living with refractory chronic cough in Montana? * Is Internet-Behavioral Cough Suppression Therapy (iBCST) efficacious? * Do iBCST participants find it satisfactory? * Is using Hyfe research app to monitor cough frequency feasible in rural areas?
Participants will complete iBCST or a placebo treatment virtually. Some participants will take part in qualitative interviews and use Hyfe research app for ambulatory cough frequency monitoring.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Missoula, Montana, 59812, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
Time frame: Pre-treatment, one-week post-treatment, one-month post-treatment
Cough-related quality of life will be measured with the Leicester Cough Questionnaire (LCQ), a valid, reliable, and repeatable measure of cough-related quality of life. The LCQ is a 19-item questionnaire containing physical, psychological, and social domains. Scores for the LCQ include mean scores for each domain (ranging from 1 to 7) and a total score calculated as the sum of the domain scores (ranging from 3 to 21). A higher score indicates better quality of life. A change in 1.3 is considered clinically significant. The LCQ total score was the primary outcome measure in this study.
Time frame: Pre-intervention, one-week post-treatment, one-month post-treatment
Cough Severity Visual Analog Scale (VAS) is a 100-millimeter line with anchors of 0 "no problem" and 100 "worst possible problem" where participants place a mark to represent the severity of their current cough problem. A reduction of at least 30-millimeters is considered clinically meaningful for the Cough Severity VAS.
University of Montana
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05599191
Chronic Cough, Cough
Jasper, Alabama, United States
View Trial DetailsNCT05888350
Chronic Cough, Cough
Guangzhou, Guangdong, China
View Trial DetailsNCT04421092
Chronic Cough, Cough
Charleston, South Carolina, United States
View Trial DetailsNCT04256733
Chronic Cough, Cough
Missoula, Montana, United States
View Trial Details